Casey Cosgrove

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny et al. · New England Journal of Medicine · 2023 · 414 citations · Full text

Medicine, Oncology, Pharmacology +16

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer

Casey Cosgrove, David Tritchler, David E. Cohn et al. · Gynecologic Oncology · 2017 · 133 citations

Medicine, Gynecology, Oncology +15

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival

Casey Cosgrove, David E. Cohn, Heather Hampel et al. · Gynecologic Oncology · 2017 · 125 citations

Medicine, Molecular Biology, Oncology +12

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

Kimberly K. Leslie, Virginia L. Filiaci, Adrianne Mallen et al. · Gynecologic Oncology · 2021 · 83 citations · Full text

Medicine, Gynecology, Oncology +12

<i>TP53</i> Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

Kristina W. Thiel, Eric J. Devor, Virginia L. Filiaci et al. · Journal of Clinical Oncology · 2022 · 77 citations · Full text

Medicine, Molecular Medicine, Oncology +16